この製品に関するご意見・ご照会・お問合せはこちら

Combination of CTLA-4 and PD-1 blockers for the treatment of cancer

Immune checkpoint regulators, such as programmed cell death protein 1 (PD-1) and Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on T cells, help to enhance the body's own immune anticancer response. Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for the activation of anti-tumor immune responses. CTLA-4 and PD-1, both inhibitory checkpoints that are commonly seen on activated T-cells have been found to be the most reliable targets for the treatment of cancer.

However, the effect is not good when administered as monotherapy. Efficacy of the combination has been shown in several published studies and is under evaluation in multiple ongoing studies. A combination of CTLA-4 and PD-1 blockers was suggested to have a synergistic effect on activation of anti-tumor immune response and to increase the response rates in patients.

ACROBiosystems has developed a series of CTLA-4 / CD28 / PD-1 / PD-L1 proteins with high bioactivity, verified by binding assay.

• Various tags and species to be selected

• High bioactivity verified by ELISA/SPR/BLI/FACS

• Suitable for immunization/antibody screening/ PK assay　

You won’t miss this！   Wonder how can these immune checkpoint proteins help your drug development?

Assay data

Protocols are available for free！

High bioactivity verified by ELISA

Quantitative Analysis of CTLA-4 x OX40 Bispecific Antibody in Human Serum by Intact Assay. Immobilized Human OX40 Protein, His Tag (MALS verified) (Cat. No. OX0-H5224) at 2 μg/mL, add increasing concentrations of CTLA-4 x OX40 bispecific antibody in 50% Human serum and then add Biotinylated Human CTLA-4, His, Avitag (Cat. No. CT4-H82E3) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 4 ng/mL (Intact assay, routinely tested).

High bioactivity verified by SPR

Biotinylated Human CTLA-4, His, Avitag (Cat. No. CT4-H82E3) captured on Biotin CAP - Series S sensor Chip can bind Yervoy (Ipilimumab) with an affinity constant of 0.635 nM as determined in an SPR assay (Biacore T200) (Routinely tested).